Thermo Fisher Scientific (NYSE:TMO) Given New $615.00 Price Target at Barclays

Thermo Fisher Scientific (NYSE:TMO) had its price objective hoisted by Barclays from $590.00 to $615.00 in a report issued on Thursday, Benzinga reports. They currently have an equal weight rating on the medical research company’s stock.

A number of other research firms have also recently weighed in on TMO. The Goldman Sachs Group upped their target price on shares of Thermo Fisher Scientific from $550.00 to $640.00 and gave the company a buy rating in a research note on Wednesday, April 10th. HSBC upped their price objective on shares of Thermo Fisher Scientific from $630.00 to $660.00 and gave the stock a buy rating in a research note on Wednesday, April 17th. Robert W. Baird decreased their price objective on shares of Thermo Fisher Scientific from $621.00 to $620.00 and set an outperform rating on the stock in a research note on Thursday. Sanford C. Bernstein reiterated a market perform rating on shares of Thermo Fisher Scientific in a research report on Monday, January 8th. Finally, Citigroup started coverage on shares of Thermo Fisher Scientific in a research report on Monday, March 18th. They set a neutral rating and a $620.00 target price on the stock. Five investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of Moderate Buy and an average target price of $606.76.

Thermo Fisher Scientific Trading Up 0.3 %

Thermo Fisher Scientific stock opened at $573.60 on Thursday. The company has a quick ratio of 1.39, a current ratio of 1.70 and a debt-to-equity ratio of 0.68. Thermo Fisher Scientific has a 12 month low of $415.60 and a 12 month high of $603.82. The company’s fifty day simple moving average is $573.60 and its 200-day simple moving average is $530.40. The stock has a market cap of $218.95 billion, a P/E ratio of 36.79, a P/E/G ratio of 2.42 and a beta of 0.80.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Wednesday, April 24th. The medical research company reported $5.11 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.70 by $0.41. Thermo Fisher Scientific had a net margin of 14.20% and a return on equity of 18.45%. The business had revenue of $10.35 billion during the quarter, compared to analyst estimates of $10.14 billion. As a group, sell-side analysts forecast that Thermo Fisher Scientific will post 21.56 EPS for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, April 15th. Shareholders of record on Friday, March 15th were issued a $0.39 dividend. The ex-dividend date was Thursday, March 14th. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. This represents a $1.56 annualized dividend and a yield of 0.27%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 10.01%.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction on Tuesday, March 12th. The shares were sold at an average price of $597.98, for a total value of $5,979,800.00. Following the sale, the chief executive officer now directly owns 123,816 shares in the company, valued at $74,039,491.68. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In other news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction on Tuesday, March 12th. The shares were sold at an average price of $597.98, for a total transaction of $5,979,800.00. Following the completion of the sale, the chief executive officer now owns 123,816 shares of the company’s stock, valued at $74,039,491.68. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Marc N. Casper sold 5,547 shares of the stock in a transaction on Thursday, February 15th. The stock was sold at an average price of $550.62, for a total transaction of $3,054,289.14. Following the sale, the chief executive officer now directly owns 43,608 shares of the company’s stock, valued at approximately $24,011,436.96. The disclosure for this sale can be found here. Over the last three months, insiders have sold 50,277 shares of company stock worth $28,513,384. Company insiders own 0.32% of the company’s stock.

Institutional Investors Weigh In On Thermo Fisher Scientific

Several large investors have recently made changes to their positions in the stock. LifeSteps Financial Inc. bought a new position in Thermo Fisher Scientific in the first quarter valued at $31,000. Northwest Financial Advisors bought a new position in Thermo Fisher Scientific in the fourth quarter valued at $29,000. True Wealth Design LLC grew its position in Thermo Fisher Scientific by 1,275.0% in the fourth quarter. True Wealth Design LLC now owns 55 shares of the medical research company’s stock valued at $29,000 after purchasing an additional 51 shares in the last quarter. Pineridge Advisors LLC bought a new position in Thermo Fisher Scientific in the fourth quarter valued at $39,000. Finally, Cape Investment Advisory Inc. grew its position in Thermo Fisher Scientific by 52.0% in the fourth quarter. Cape Investment Advisory Inc. now owns 76 shares of the medical research company’s stock valued at $40,000 after purchasing an additional 26 shares in the last quarter. Institutional investors own 89.23% of the company’s stock.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.